Global Osteoporosis Drugs Market Size Study & Forecast, by Drug Type (Parathyroid Hormone Therapy, Bisphosphonates, Calcitonin, RANKL Inhibitors, Other Drug Types), by Route of Administration (Oral, Injectable, Others), and Regional Analysis, 2023-2030
Global Osteoporosis Drugs Market is valued at approximately USD 8.93 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 3.9% over the forecast period 2023-2030. Osteoporosis is a medical condition that is characterized by low bone quality and density in humans. Additionally, this health issue causes the bones to become porous, which makes them more brittle and susceptible to fractures. The disorder is caused by an excess of the hormone parathyroid. The condition results in serious fractures, which are harmful to the patient's health. Because of this, the problem needs to be treated, which involves taking medications for osteoporosis. RANK ligand inhibitors, parathyroid hormone treatment, calcitonin, and selective estrogen inhibitors modulators (SERM) are several medications available in the market. These medications are administered in ways including orally and intravenously. The surge in the geriatric population, adoption of a sedentary lifestyle, increasing healthcare expenditure, and rise in hip fractures are the several factors that are propelling the market demand during the estimated period.
In addition, the increase in the incidences of osteoporosis is playing a major role that is stipulating market growth across the globe. The prevalence of osteoporosis is increasing due to changing lifestyle habits, lack of physical activity, and poor diet. This has led to an increase in the demand for osteoporosis drugs. The International Osteoporosis Foundation stated that in 2020, 1 in 5 men and 1 in 3 women more than the age of 50 are likely to experience osteoporosis fractures in their life. Additionally, according to the International Osteoporosis Foundation (IOF), in 2019, the annual number of osteoporotic fractures in Europe accounted for 4.28 million, which is projected to increase and reach 5.34 million in 2034. The percentage growth during the 15-year period is likely to differ significantly by nation, from a low 8% growth (Latvia) to 58% (Ireland). Also, as per the National Osteoporosis Foundation (NOF), in 2020, over 10 million people in the United States have been diagnosed with osteoporosis, which is common in menopausal women. Consequentially, the rising cases of osteoporosis are significantly contributing to the market expansion. Moreover, the high growth prospects in emerging markets, as well as the increasing investment in R&D activities present various lucrative opportunities over the forecasting years. However, the stringent regulations on the drug approval process and the side effects of osteoporosis drugs are challenging the market growth throughout the forecast period of 2023-2030.
The key regions considered for the Global Osteoporosis Drugs Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the surge in the incidence of osteoporosis, the presence of key players, and growing R&D investment. Whereas, Asia Pacific is expected to grow at the fastest growing over the forecasting years. The growing awareness regarding the use of osteoporosis drugs, rising government initiatives, increase in hip fractures, changing lifestyle, and growing demand for generic drugs are significantly propelling the market demand across the region.
Major market players included in this report are:
Amgen Inc.
Eli Lilly and Company
F. HOFFMANN-LA ROCHE LTD.
Radius Health, Inc.
Merck & Co. Inc.
Novartis International AG (Sandoz)
Pfizer Inc.
Sun Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.
Recent Developments in the Market:
In August 2021, The Drug Controller General of India (DCGI) granted Enzene Biosciences Ltd. marketing authorization (MA) for their biosimilar medication, denosumab, which is approved for the treatment of adult osteoporosis.
Global Osteoporosis Drugs Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered - Drug Type, Route of Administration, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Customization Scope - Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Drug Type:
Parathyroid Hormone Therapy
Bisphosphonates
Calcitonin
RANKL Inhibitors
Other Drug Types
By Route of Administration:
Oral
Injectable
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa
In addition, the increase in the incidences of osteoporosis is playing a major role that is stipulating market growth across the globe. The prevalence of osteoporosis is increasing due to changing lifestyle habits, lack of physical activity, and poor diet. This has led to an increase in the demand for osteoporosis drugs. The International Osteoporosis Foundation stated that in 2020, 1 in 5 men and 1 in 3 women more than the age of 50 are likely to experience osteoporosis fractures in their life. Additionally, according to the International Osteoporosis Foundation (IOF), in 2019, the annual number of osteoporotic fractures in Europe accounted for 4.28 million, which is projected to increase and reach 5.34 million in 2034. The percentage growth during the 15-year period is likely to differ significantly by nation, from a low 8% growth (Latvia) to 58% (Ireland). Also, as per the National Osteoporosis Foundation (NOF), in 2020, over 10 million people in the United States have been diagnosed with osteoporosis, which is common in menopausal women. Consequentially, the rising cases of osteoporosis are significantly contributing to the market expansion. Moreover, the high growth prospects in emerging markets, as well as the increasing investment in R&D activities present various lucrative opportunities over the forecasting years. However, the stringent regulations on the drug approval process and the side effects of osteoporosis drugs are challenging the market growth throughout the forecast period of 2023-2030.
The key regions considered for the Global Osteoporosis Drugs Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the surge in the incidence of osteoporosis, the presence of key players, and growing R&D investment. Whereas, Asia Pacific is expected to grow at the fastest growing over the forecasting years. The growing awareness regarding the use of osteoporosis drugs, rising government initiatives, increase in hip fractures, changing lifestyle, and growing demand for generic drugs are significantly propelling the market demand across the region.
Major market players included in this report are:
Amgen Inc.
Eli Lilly and Company
F. HOFFMANN-LA ROCHE LTD.
Radius Health, Inc.
Merck & Co. Inc.
Novartis International AG (Sandoz)
Pfizer Inc.
Sun Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.
Recent Developments in the Market:
In August 2021, The Drug Controller General of India (DCGI) granted Enzene Biosciences Ltd. marketing authorization (MA) for their biosimilar medication, denosumab, which is approved for the treatment of adult osteoporosis.
Global Osteoporosis Drugs Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered - Drug Type, Route of Administration, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Customization Scope - Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Drug Type:
Parathyroid Hormone Therapy
Bisphosphonates
Calcitonin
RANKL Inhibitors
Other Drug Types
By Route of Administration:
Oral
Injectable
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa
CHAPTER 1. EXECUTIVE SUMMARY
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
1.2.1. Osteoporosis Drugs Market, by Region, 2020-2030 (USD Billion)
1.2.2. Osteoporosis Drugs Market, by Drug Type, 2020-2030 (USD Billion)
1.2.3. Osteoporosis Drugs Market, by Route of Administration, 2020-2030 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
CHAPTER 2. GLOBAL OSTEOPOROSIS DRUGS MARKET DEFINITION AND SCOPE
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Industry Evolution
2.2.2. Scope of the Study
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
CHAPTER 3. GLOBAL OSTEOPOROSIS DRUGS MARKET DYNAMICS
3.1. Osteoporosis Drugs Market Impact Analysis (2020-2030)
3.1.1. Market Drivers
3.1.1.1. Increase in the incidences of osteoporosis
3.1.1.2. Rising hip fractures
3.1.2. Market Challenges
3.1.2.1. Stringent regulations on drug approval process
3.1.2.2. Side effects of osteoporosis drugs
3.1.3. Market Opportunities
3.1.3.1. High growth prospects in emerging markets
3.1.3.2. Increasing investment in the R&D activities
CHAPTER 4. GLOBAL OSTEOPOROSIS DRUGS MARKET INDUSTRY ANALYSIS
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Porter’s 5 Force Impact Analysis
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.3.5. Environmental
4.3.6. Legal
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. COVID-19 Impact Analysis
4.7. Disruptive Trends
4.8. Industry Expert Perspective
4.9. Analyst Recommendation & Conclusion
CHAPTER 5. GLOBAL OSTEOPOROSIS DRUGS MARKET, BY DRUG TYPE
5.1. Market Snapshot
5.2. Global Osteoporosis Drugs Market by Drug Type, Performance - Potential Analysis
5.3. Global Osteoporosis Drugs Market Estimates & Forecasts by Drug Type 2020-2030 (USD Billion)
5.4. Osteoporosis Drugs Market, Sub Segment Analysis
5.4.1. Parathyroid Hormone Therapy
5.4.2. Bisphosphonates
5.4.3. Calcitonin
5.4.4. RANKL Inhibitors
5.4.5. Other Drug Types
CHAPTER 6. GLOBAL OSTEOPOROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION
6.1. Market Snapshot
6.2. Global Osteoporosis Drugs Market by Route of Administration, Performance - Potential Analysis
6.3. Global Osteoporosis Drugs Market Estimates & Forecasts by Route of Administration 2020-2030 (USD Billion)
6.4. Osteoporosis Drugs Market, Sub Segment Analysis
6.4.1. Oral
6.4.2. Injectable
6.4.3. Others
CHAPTER 7. GLOBAL OSTEOPOROSIS DRUGS MARKET, REGIONAL ANALYSIS
7.1. Top Leading Countries
7.2. Top Emerging Countries
7.3. Osteoporosis Drugs Market, Regional Market Snapshot
7.4. North America Osteoporosis Drugs Market
7.4.1. U.S. Osteoporosis Drugs Market
7.4.1.1. Drug Type breakdown estimates & forecasts, 2020-2030
7.4.1.2. Route of Administration breakdown estimates & forecasts, 2020-2030
7.4.2. Canada Osteoporosis Drugs Market
7.5. Europe Osteoporosis Drugs Market Snapshot
7.5.1. U.K. Osteoporosis Drugs Market
7.5.2. Germany Osteoporosis Drugs Market
7.5.3. France Osteoporosis Drugs Market
7.5.4. Spain Osteoporosis Drugs Market
7.5.5. Italy Osteoporosis Drugs Market
7.5.6. Rest of Europe Osteoporosis Drugs Market
7.6. Asia-Pacific Osteoporosis Drugs Market Snapshot
7.6.1. China Osteoporosis Drugs Market
7.6.2. India Osteoporosis Drugs Market
7.6.3. Japan Osteoporosis Drugs Market
7.6.4. Australia Osteoporosis Drugs Market
7.6.5. South Korea Osteoporosis Drugs Market
7.6.6. Rest of Asia Pacific Osteoporosis Drugs Market
7.7. Latin America Osteoporosis Drugs Market Snapshot
7.7.1. Brazil Osteoporosis Drugs Market
7.7.2. Mexico Osteoporosis Drugs Market
7.8. Middle East & Africa Osteoporosis Drugs Market
7.8.1. Saudi Arabia Osteoporosis Drugs Market
7.8.2. South Africa Osteoporosis Drugs Market
7.8.3. Rest of Middle East & Africa Osteoporosis Drugs Market
CHAPTER 8. COMPETITIVE INTELLIGENCE
8.1. Key Company SWOT Analysis
8.1.1. Company
8.1.2. Company
8.1.3. Company
8.2. Top Market Strategies
8.3. Company Profiles
8.3.1. Amgen Inc.
8.3.1.1. Key Information
8.3.1.2. Overview
8.3.1.3. Financial (Subject to Data Availability)
8.3.1.4. Product Summary
8.3.1.5. Recent Developments
8.3.2. Eli Lilly and Company
8.3.3. F. HOFFMANN-LA ROCHE LTD.
8.3.4. Radius Health, Inc.
8.3.5. Merck & Co. Inc.
8.3.6. Novartis International AG (Sandoz)
8.3.7. Pfizer Inc.
8.3.8. Sun Pharmaceutical Industries Ltd.
8.3.9. Takeda Pharmaceutical Company Limited
8.3.10. Teva Pharmaceutical Industries Ltd.
CHAPTER 9. RESEARCH PROCESS
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.2. Research Attributes
9.3. Research Assumption
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
1.2.1. Osteoporosis Drugs Market, by Region, 2020-2030 (USD Billion)
1.2.2. Osteoporosis Drugs Market, by Drug Type, 2020-2030 (USD Billion)
1.2.3. Osteoporosis Drugs Market, by Route of Administration, 2020-2030 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
CHAPTER 2. GLOBAL OSTEOPOROSIS DRUGS MARKET DEFINITION AND SCOPE
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Industry Evolution
2.2.2. Scope of the Study
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
CHAPTER 3. GLOBAL OSTEOPOROSIS DRUGS MARKET DYNAMICS
3.1. Osteoporosis Drugs Market Impact Analysis (2020-2030)
3.1.1. Market Drivers
3.1.1.1. Increase in the incidences of osteoporosis
3.1.1.2. Rising hip fractures
3.1.2. Market Challenges
3.1.2.1. Stringent regulations on drug approval process
3.1.2.2. Side effects of osteoporosis drugs
3.1.3. Market Opportunities
3.1.3.1. High growth prospects in emerging markets
3.1.3.2. Increasing investment in the R&D activities
CHAPTER 4. GLOBAL OSTEOPOROSIS DRUGS MARKET INDUSTRY ANALYSIS
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Porter’s 5 Force Impact Analysis
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.3.5. Environmental
4.3.6. Legal
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. COVID-19 Impact Analysis
4.7. Disruptive Trends
4.8. Industry Expert Perspective
4.9. Analyst Recommendation & Conclusion
CHAPTER 5. GLOBAL OSTEOPOROSIS DRUGS MARKET, BY DRUG TYPE
5.1. Market Snapshot
5.2. Global Osteoporosis Drugs Market by Drug Type, Performance - Potential Analysis
5.3. Global Osteoporosis Drugs Market Estimates & Forecasts by Drug Type 2020-2030 (USD Billion)
5.4. Osteoporosis Drugs Market, Sub Segment Analysis
5.4.1. Parathyroid Hormone Therapy
5.4.2. Bisphosphonates
5.4.3. Calcitonin
5.4.4. RANKL Inhibitors
5.4.5. Other Drug Types
CHAPTER 6. GLOBAL OSTEOPOROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION
6.1. Market Snapshot
6.2. Global Osteoporosis Drugs Market by Route of Administration, Performance - Potential Analysis
6.3. Global Osteoporosis Drugs Market Estimates & Forecasts by Route of Administration 2020-2030 (USD Billion)
6.4. Osteoporosis Drugs Market, Sub Segment Analysis
6.4.1. Oral
6.4.2. Injectable
6.4.3. Others
CHAPTER 7. GLOBAL OSTEOPOROSIS DRUGS MARKET, REGIONAL ANALYSIS
7.1. Top Leading Countries
7.2. Top Emerging Countries
7.3. Osteoporosis Drugs Market, Regional Market Snapshot
7.4. North America Osteoporosis Drugs Market
7.4.1. U.S. Osteoporosis Drugs Market
7.4.1.1. Drug Type breakdown estimates & forecasts, 2020-2030
7.4.1.2. Route of Administration breakdown estimates & forecasts, 2020-2030
7.4.2. Canada Osteoporosis Drugs Market
7.5. Europe Osteoporosis Drugs Market Snapshot
7.5.1. U.K. Osteoporosis Drugs Market
7.5.2. Germany Osteoporosis Drugs Market
7.5.3. France Osteoporosis Drugs Market
7.5.4. Spain Osteoporosis Drugs Market
7.5.5. Italy Osteoporosis Drugs Market
7.5.6. Rest of Europe Osteoporosis Drugs Market
7.6. Asia-Pacific Osteoporosis Drugs Market Snapshot
7.6.1. China Osteoporosis Drugs Market
7.6.2. India Osteoporosis Drugs Market
7.6.3. Japan Osteoporosis Drugs Market
7.6.4. Australia Osteoporosis Drugs Market
7.6.5. South Korea Osteoporosis Drugs Market
7.6.6. Rest of Asia Pacific Osteoporosis Drugs Market
7.7. Latin America Osteoporosis Drugs Market Snapshot
7.7.1. Brazil Osteoporosis Drugs Market
7.7.2. Mexico Osteoporosis Drugs Market
7.8. Middle East & Africa Osteoporosis Drugs Market
7.8.1. Saudi Arabia Osteoporosis Drugs Market
7.8.2. South Africa Osteoporosis Drugs Market
7.8.3. Rest of Middle East & Africa Osteoporosis Drugs Market
CHAPTER 8. COMPETITIVE INTELLIGENCE
8.1. Key Company SWOT Analysis
8.1.1. Company
8.1.2. Company
8.1.3. Company
8.2. Top Market Strategies
8.3. Company Profiles
8.3.1. Amgen Inc.
8.3.1.1. Key Information
8.3.1.2. Overview
8.3.1.3. Financial (Subject to Data Availability)
8.3.1.4. Product Summary
8.3.1.5. Recent Developments
8.3.2. Eli Lilly and Company
8.3.3. F. HOFFMANN-LA ROCHE LTD.
8.3.4. Radius Health, Inc.
8.3.5. Merck & Co. Inc.
8.3.6. Novartis International AG (Sandoz)
8.3.7. Pfizer Inc.
8.3.8. Sun Pharmaceutical Industries Ltd.
8.3.9. Takeda Pharmaceutical Company Limited
8.3.10. Teva Pharmaceutical Industries Ltd.
CHAPTER 9. RESEARCH PROCESS
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.2. Research Attributes
9.3. Research Assumption
LIST OF TABLES
TABLE 1. Global Osteoporosis Drugs Market, report scope
TABLE 2. Global Osteoporosis Drugs Market estimates & forecasts by Region 2020-2030 (USD Billion)
TABLE 3. Global Osteoporosis Drugs Market estimates & forecasts by Drug Type 2020-2030 (USD Billion)
TABLE 4. Global Osteoporosis Drugs Market estimates & forecasts by Route of Administration 2020-2030 (USD Billion)
TABLE 5. Global Osteoporosis Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 6. Global Osteoporosis Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 7. Global Osteoporosis Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 8. Global Osteoporosis Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 9. Global Osteoporosis Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 10. Global Osteoporosis Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 11. Global Osteoporosis Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 12. Global Osteoporosis Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 13. Global Osteoporosis Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 14. Global Osteoporosis Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 15. U.S. Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 16. U.S. Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 17. U.S. Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 18. Canada Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 19. Canada Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 20. Canada Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 21. UK Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 22. UK Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 23. UK Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 24. Germany Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 25. Germany Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 26. Germany Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 27. France Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 28. France Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 29. France Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 30. Italy Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 31. Italy Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 32. Italy Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 33. Spain Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 34. Spain Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 35. Spain Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 36. RoE Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 37. RoE Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 38. RoE Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 39. China Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 40. China Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 41. China Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 42. India Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 43. India Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 44. India Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 45. Japan Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 46. Japan Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 47. Japan Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 48. South Korea Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 49. South Korea Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 50. South Korea Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 51. Australia Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 52. Australia Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 53. Australia Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 54. RoAPAC Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 55. RoAPAC Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 56. RoAPAC Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 57. Brazil Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 58. Brazil Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 59. Brazil Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 60. Mexico Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 61. Mexico Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 62. Mexico Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 63. RoLA Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 64. RoLA Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 65. RoLA Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 66. Saudi Arabia Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 67. South Africa Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 68. RoMEA Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 69. List of secondary sources, used in the study of global Osteoporosis Drugs Market
TABLE 70. List of primary sources, used in the study of global Osteoporosis Drugs Market
TABLE 71. Years considered for the study
TABLE 72. Exchange rates considered
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
TABLE 1. Global Osteoporosis Drugs Market, report scope
TABLE 2. Global Osteoporosis Drugs Market estimates & forecasts by Region 2020-2030 (USD Billion)
TABLE 3. Global Osteoporosis Drugs Market estimates & forecasts by Drug Type 2020-2030 (USD Billion)
TABLE 4. Global Osteoporosis Drugs Market estimates & forecasts by Route of Administration 2020-2030 (USD Billion)
TABLE 5. Global Osteoporosis Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 6. Global Osteoporosis Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 7. Global Osteoporosis Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 8. Global Osteoporosis Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 9. Global Osteoporosis Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 10. Global Osteoporosis Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 11. Global Osteoporosis Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 12. Global Osteoporosis Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 13. Global Osteoporosis Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 14. Global Osteoporosis Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 15. U.S. Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 16. U.S. Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 17. U.S. Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 18. Canada Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 19. Canada Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 20. Canada Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 21. UK Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 22. UK Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 23. UK Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 24. Germany Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 25. Germany Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 26. Germany Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 27. France Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 28. France Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 29. France Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 30. Italy Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 31. Italy Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 32. Italy Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 33. Spain Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 34. Spain Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 35. Spain Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 36. RoE Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 37. RoE Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 38. RoE Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 39. China Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 40. China Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 41. China Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 42. India Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 43. India Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 44. India Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 45. Japan Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 46. Japan Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 47. Japan Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 48. South Korea Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 49. South Korea Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 50. South Korea Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 51. Australia Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 52. Australia Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 53. Australia Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 54. RoAPAC Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 55. RoAPAC Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 56. RoAPAC Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 57. Brazil Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 58. Brazil Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 59. Brazil Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 60. Mexico Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 61. Mexico Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 62. Mexico Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 63. RoLA Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 64. RoLA Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 65. RoLA Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 66. Saudi Arabia Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 67. South Africa Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 68. RoMEA Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 69. List of secondary sources, used in the study of global Osteoporosis Drugs Market
TABLE 70. List of primary sources, used in the study of global Osteoporosis Drugs Market
TABLE 71. Years considered for the study
TABLE 72. Exchange rates considered
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
LIST OF FIGURES
FIG 1. Global Osteoporosis Drugs Market, research methodology
FIG 2. Global Osteoporosis Drugs Market, Market estimation techniques
FIG 3. Global Market size estimates & forecast methods
FIG 4. Global Osteoporosis Drugs Market, key trends 2022
FIG 5. Global Osteoporosis Drugs Market, growth prospects 2023-2030
FIG 6. Global Osteoporosis Drugs Market, porters 5 force model
FIG 7. Global Osteoporosis Drugs Market, pest analysis
FIG 8. Global Osteoporosis Drugs Market, value chain analysis
FIG 9. Global Osteoporosis Drugs Market by segment, 2020 & 2030 (USD Billion)
FIG 10. Global Osteoporosis Drugs Market by segment, 2020 & 2030 (USD Billion)
FIG 11. Global Osteoporosis Drugs Market by segment, 2020 & 2030 (USD Billion)
FIG 12. Global Osteoporosis Drugs Market by segment, 2020 & 2030 (USD Billion)
FIG 13. Global Osteoporosis Drugs Market by segment, 2020 & 2030 (USD Billion)
FIG 14. Global Osteoporosis Drugs Market, regional snapshot 2020 & 2030
FIG 15. North America Osteoporosis Drugs Market 2020 & 2030 (USD Billion)
FIG 16. Europe Osteoporosis Drugs Market 2020 & 2030 (USD Billion)
FIG 17. Asia pacific Osteoporosis Drugs Market 2020 & 2030 (USD Billion)
FIG 18. Latin America Osteoporosis Drugs Market 2020 & 2030 (USD Billion)
FIG 19. Middle East & Africa Osteoporosis Drugs Market 2020 & 2030 (USD Billion)
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
FIG 1. Global Osteoporosis Drugs Market, research methodology
FIG 2. Global Osteoporosis Drugs Market, Market estimation techniques
FIG 3. Global Market size estimates & forecast methods
FIG 4. Global Osteoporosis Drugs Market, key trends 2022
FIG 5. Global Osteoporosis Drugs Market, growth prospects 2023-2030
FIG 6. Global Osteoporosis Drugs Market, porters 5 force model
FIG 7. Global Osteoporosis Drugs Market, pest analysis
FIG 8. Global Osteoporosis Drugs Market, value chain analysis
FIG 9. Global Osteoporosis Drugs Market by segment, 2020 & 2030 (USD Billion)
FIG 10. Global Osteoporosis Drugs Market by segment, 2020 & 2030 (USD Billion)
FIG 11. Global Osteoporosis Drugs Market by segment, 2020 & 2030 (USD Billion)
FIG 12. Global Osteoporosis Drugs Market by segment, 2020 & 2030 (USD Billion)
FIG 13. Global Osteoporosis Drugs Market by segment, 2020 & 2030 (USD Billion)
FIG 14. Global Osteoporosis Drugs Market, regional snapshot 2020 & 2030
FIG 15. North America Osteoporosis Drugs Market 2020 & 2030 (USD Billion)
FIG 16. Europe Osteoporosis Drugs Market 2020 & 2030 (USD Billion)
FIG 17. Asia pacific Osteoporosis Drugs Market 2020 & 2030 (USD Billion)
FIG 18. Latin America Osteoporosis Drugs Market 2020 & 2030 (USD Billion)
FIG 19. Middle East & Africa Osteoporosis Drugs Market 2020 & 2030 (USD Billion)
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
